Abeona Therapeutics Inc. (NYSE: ABEO) was founded in 1989, formerly PlasmaTech Biopharmaceuticals, Inc., changed to its current name in June 2015, headquartered in Dallas, Texas, with 88 full-time employees. It is a clinical-stage biopharmaceutical the company.
Abeona Therapeutics (ABEO):
Abeona Therapeutics is a biopharmaceutical company that focuses on the development and delivery of gene therapy and plasma-based products to treat serious and life-threatening rare diseases. Abeona Therapeutics’ product candidates mainly include:
- AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH): Adeno-associated virus (AAV)-based gene therapy for the treatment of San Filippo syndrome (MPS IIIB and IIIA);
- ABO-201 (scAAV9 CLN3): Gene therapy to treat adolescent Batten disease (JBD);
- ABO-301 (AAV LK19 FANCC): CRISPR/Cas9-based gene therapy to treat Fanconi anemia (FA) and other rare blood diseases;
In addition, Abeona Therapeutics is developing rare plasma protein therapies, including SDF AlphaT (α-1 protease inhibitor).
In addition, Abeona Therapeutics is also involved in the sale of MuGard and ProctiGard, the former is a treatment for oral wounds, stomatitis, oral ulcers and traumatic ulcers, and the latter is used for the treatment of rectal mucositis and proctitis.